Lilly's Global COVID-19 Response Archives

News Releases, Resources and Multimedia - 2022

November

• Lilly's statement on FDA’s de-authorization of bebtelovimab in the U.S. (November 30)

August

• Lilly’s commercialization of bebtelovimab for COVID-19 under Emergency Use Authorization (August 8)

June

• Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options (June 29)

May

• Lilly’s statement on bebtelovimab which maintains neutralization activity against all known variants in circulation (May 18)

• FDA Approves Lilly and Incyte’s OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 (May 11)

February

• Lilly’s bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 (February 11)

• Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options (February 10)

January

• Lilly's statement on the FDA's Fact Sheet update for bamlanivimab and etesevimab to include a new Limitation for Authorized Use (January 24)

• New WHO COVID-19 treatment guidelines now strongly recommend Lilly’s baricitinib for patients with severe or critical COVID-19 (January 21)

News Releases, Resources and Multimedia - 2021

December

• Lilly’s statement on its monoclonal antibody therapies neutralization activity against the Omicron variant of concern (December 20)

• Lilly's statement on the testing process of COVID-19 antibody therapies against the Omicron variant of concern (December 14)

• Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12 (December 3)

November

• Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19 (November 2)

September

• Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19 (September 21)

• Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 (September 16)

• Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 (September 15)

August

• Lilly’s statement on the reopening of distribution for COVID-19 antibody therapies in the U.S. (August 27)

• Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation (August 3)

July

• FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen (July 29)

June

• Lilly's statement on direct ordering of COVID-19 antibody therapies in the U.S. (June 29)

May

• Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries (May 4)

• Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements (May 4)

April

• Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S. (April 15)

• Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together (April 12)

• Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients (April 8)

• GotMyShotCampaign.com, a community-wide effort supported by local government, health care, nonprofit and corporate partners to share facts about COVID-19 vaccines

March

• Lilly, Vir Biotechnology and GSK announce positive topline data from the Phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19 (March 29)

• Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19 (March 10)

• EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union (March 5)

• COVID-19 antibody allocation and transparency tracker

• Lilly's 2020 Integrated Summary Report, including COVID-19 information and stories

February

• Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19 (February 26)

• Lilly’s bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA Emergency Use Authorization for COVID-19 (February 9)

• Lilly partners with area health systems to help enable access to important antibody infusion therapies for COVID-19 patients (February 1)

January

• Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 (January 27)

• New data show treatment with Lilly’s neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent (January 26)

• Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents (January 21)

• Article: "Could monoclonal antibodies help in your COVID-19 treatment journey?" (January 15)

News Releases, Resources and Multimedia - 2020

December

• Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico (December 18)

• Data from ACTT-2 trial of baricitinib in hospitalized COVID-19 patients supportive of the EUA published in New England Journal of Medicine (December 11)

• Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 (December 4)

• Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19 (December 2)

November

• Fourth iteration of COVID-19 treatment trial underway (November 25)

• Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19 (November 20)

• Baricitinib receives Emergency Use Authorization by the U.S. Food and Drug Administration for the treatment of hospitalized patients with COVID-19 (November 19)

• Article: "Lilly's COVID-19 science leads to another FDA Emergency Use Authorization" (November 19)

• Article: "When the world called for help with COVID-19, we were ready" (November 10)

• Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA Emergency Use Authorization for the treatment of recently diagnosed COVID-19 (November 9)

• Article: "Dave Ricks shares about Lilly's FDA Emergency Use Authorization for a neutralizing antibody" (November 9)

October

• Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19 (October 28)

• CEO Dave Ricks shares Lilly's principles of COVID-19 antibody therapy pricing and access (October 28)

• Infographic: Lilly's access and affordability principles for our neutralizing antibodies (October 28)

• Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 patients published in New England Journal of Medicine (October 28)

• Infographic: Lilly's COVID-19 quest - key clinical trials for neutralizing antibodies (October 27)

• Lilly statement regarding NIH's ACTIV-3 clinical trial (October 26)

• Lilly statement on our commitment to quality manufacturing (October 20)

• Lilly statement on the NIAID decision to pause enrollment in ACTIV-3 clinical trial (October 14)

• Baricitinib has significant effect on recovery time, most effective in COVID-19 patients requiring oxygen (October 8)

• Lilly announces arrangement for supply of potential COVID-19 antibody therapy for low- and middle-income countries (October 8)

• Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs (October 7)

• Article: "What does it take to manufacturing neutralizing antibodies?" (October 7)

September

• Life science companies and the Bill & Melinda Gates Foundation: commitments to expanding global access for COVID-19 diagnostics, therapeutics and vaccines (September 30)

• STAT News: "Three lessons from COVID-19 on accelerating biopharma innovation," by Anne White, Lilly Oncology president (September 18)

• Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies (September 17)

• Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting (September 16)

• Lilly's neutralizing antibodies and COVID-19 fact sheet (September 16)

• Innovation for early detection of global pandemic and a coordinated response system, a Congressional Hispanic Caucus Institute event featuring Lilly senior vice president and chief scientific officer Dan Skovronsky (September 16)

• Baricitinib in combination with remdesivir reduces time to recovery in hospitalized patients with COVID-19 in NIAID-sponsored ACTT-2 trial (September 14)

August

• Lilly's COVID-19 fact sheet

• NIH clinical trial to test antibodies and other experimental therapeutics for mild and moderate COVID-19 (August 4)

• NIH launches clinical trial to test antibody treatment in hospitalized COVID-19 patients (August 4)

• Lilly initiates Phase 3 trial of LY-CoV555 for prevention of COVID-19 at long-term care facilities in partnership with the National Institute of Allergy and Infectious Diseases (NIAID) (August 3)

July

• Wall Street Journal video: "Scientists work to produce COVID-19 treatments under new conditions" (July 20)

• Politico: "Four ways drug companies can ease racial disparities," by Lilly executives (July 20)

• Lilly's COVID-19 drive-through testing analytics dashboard (July 7)

June

• Lilly begins a Phase 3 clinical trial with baricitinib for hospitalized COVID-19 patients (June 15)

• Lilly announces start of a Phase 1 study for its second potential COVID-19 antibody treatment (June 8)

• Lilly begins world's first study of a potential COVID-19 antibody treatment in humans (June 1)

May

• Lilly CEO Dave Ricks' Indianapolis Star Op-ed: "As Indiana reopens, let's proceed with caution and data" (May 5)

• Lilly and Junshi Biosciences to co-develop antibody therapies for the prevention and treatment of COVID-19 (May 4)

April

• Indianapolis E-Learning Fund sends $1.5 million to Marion County districts and charter schools (April 27)

• NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options (April 17)

• Lilly begins clinical testing of therapies for COVID-19 (April 10)

• Indianapolis E-Learning Fund launches with more than $2.6 million (April 8)

• New $35 co-pay now available through Lilly Insulin Value Program in response to COVID-19 crisis in U.S. (April 7)

• Gov. Holcomb and Mayor Hogsett announce coalition to flatten the COVID-19 curve across state; public invited to make commitment (April 1)

• Lilly to expand drive-through COVID-19 testing (April 1)

• Medical professionals across Merck, Pfizer and Lilly activate to support health systems, first responders and patients amid COVID-19 pandemic (April 1)

March

• Lilly CEO Dave Ricks' letter to Americans who rely on Lilly insulin (March 30)

• Lilly update on supply chain reliability and position on stockpiling (March 26)

• Life sciences companies commit expertise and assets to fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation (March 26)

• 46 organizations receive immediate grants from Central Indiana COVID-19 Economic Relief Fund (March 26)

• Updates from Lilly on supply of medicines and insulin affordability (March 24)

• Lilly provides update on clinical trial activities during COVID-19 pandemic (March 23)

• Media teleconference regarding COVID-19 (March 18; audio only)

• Lilly, Indiana State Department of Health partner to accelerate COVID-19 testing using Lilly Research Laboratories (March 18)

• AbCellera and Lilly to co-develop antibody therapies for the treatment of COVID-19 (March 12)